A detailed 3D molecular model of an antibody-drug conjugate (ADC). The antibody is represented by a large, complex structure of blue and purple spheres. Several smaller, orange-colored drug molecules are attached to the antibody. The background is a dark blue gradient with some light blue and purple bokeh effects.

# Integrated Translational Services for Antibody- Drug Conjugates (ADCs) Development



## Access a full suite of integrated services for your ADC development

Crown Bioscience's fully integrated ADC development services accelerate ADC development, reduce risks, and deliver cost-efficient, reliable results. The platform utilizes the world's largest collection of well characterized patient-derived models, ensuring the optimal model for every stage of development.

- Receive customized development plans tailored to specific project needs from scientists experienced in ADC development with a proven track record of success.
- Join a growing list of successful ADC projects that demonstrate Crown Bioscience's capability to deliver impactful results


### Leverage diverse model selection

- Evaluate ADC activity on a range of models across various patient ethnicities, different disease stages, as well as on primary tumor-derived and metastatic models.
- Robustly test for primary and secondary resistance to ADC candidates using a large array of diverse and heterogeneous tumor models including rare mutations, or bioluminescent or fluorescent probes.
- Seamlessly transition from *in vitro* to *in vivo* pharmacology services, including model selection for efficacy testing, PDX models, CDX models with imaging, and efficacy/bystander effect testing.
- Screen organoid panels across 500 morphological and phenotypic data points, ideal for assessing mechanisms of resistance.
- Fast-track your ADC candidate development with NGS/ AI-based tumor-associated antigen discovery and model selection.

### Capitalize on services optimized for ADC development

- Utilize advanced ADC development with site-specific conjugation techniques to optimize linker payloads, along with bioconjugation, physicochemical characterization, drug-to-antibody ratio (DAR), and endotoxin testing to ensure optimal drug performance.
- Leverage antibody generation services, including antigen design and production, hybridoma generation, antibody screening (binding, ADCC, internalization), and deep phase screening for lead optimization.
- Perform mass spectrometry analysis to precisely assess pharmacokinetics (PK) and DAR, providing reliable data for informed decision-making in development.
- Integrate small molecules to enhance the therapeutic potential of ADCs, expanding the options for optimized strategies.
- Gain a deeper understanding of the mechanisms of action for your monoclonal antibody therapies, enhancing their effectiveness in targeting cancer cells.

## Robust, fully integrated ADC development services drastically reduce timelines while improving data quality



Leverage the power of the world's largest collection of pre-clinical models

## Complimentary Cancer Model Databases


### Quickly Find Preclinical Models to Fit Your Research Needs

By utilizing our free cancer model databases, researchers gain a significant advantage in their preclinical oncology studies with time and cost savings. Access to diverse and well-characterized tumor models, along with extensive profiling and pharmacologic data, empowers researchers like you to make confident and well-informed decisions during oncology drug discovery.


<https://hubs.la/Q02VJ3pc0>




Target Gene expression (RNAseq)



Target protein expression (Proteomics)



Target protein expression (IHC)



Curate the optimal models based on target/antigen expressions or key biomarkers



### PDX Model Database

Clinically Relevant PDX Models

Access 2,500+ global PDX models. Tailor your selections based on indication, drug responses, patient histories, and multiomics data for precision in your studies.



### Organoid Models Database

Exclusive Organoid Models

Utilize specialized *in vitro* models using HUB protocols. Easily access Vital POXO data including histopathology, IC<sub>50</sub>, and genomics to ensure research accuracy.



### IO Murine Models Database

Diverse 10 Murine Models

Broaden possibilities with Syngeneic, GEMM, murine tumor homographs, humanized genetically modified mouse models, and more to enhance immunology research.



### Cell Line and CDX Database

Comprehensive Cell line and CDX Resources

Search from 900+ cancer cell lines and 200+ CDX models. View and select models available for screening and faster *in vitro* to *in vivo* study translation.

Get in touch



US: +1 858 622 2900  
UK: +44 (0)1530 234871

busdev@crownbio.com  
www.crownbio.com

